The Year in Biotech and What’s Ahead in 2023
The Bio Report
00:00
Alzheimer's and Blowups
Danny Cevallos: We've gotten so used to these phase three blowups and Alzheimer's. You think we're finally beyond that? He says there are differences between the catamab and adju-catamab, you know, adju-help. And as do sort of the trials that you run and the patient population that you enroll,. he writes. "It also may also limit the kind of the potential, right? Because you need to find the right patient"
Transcript
Play full episode
